In: Molecular oncology, 2015, vol. 9, no. 6, p. 1194-1206
STAT3 is a key element in many oncogenic pathways and, like other transcription factors, is an attractive target for development of novel anticancer drugs. However, interfering with STAT3 functions has been a difficult task and very few small molecule inhibitors have made their way to the clinic. OPB‐31121, an anticancer compound currently in clinical trials, has been reported to affect...
|
In: The Journal of Membrane Biology, 2006, vol. 213, no. 1, p. 1-9
|
In: Plant Molecular Biology, 2009, vol. 69, no. 1-2, p. 47-56
|
In: Applied Microbiology and Biotechnology, 2007, vol. 74, no. 4, p. 791-804
|
In: FEMS Microbiology Letters, 1998, vol. 163, no. 1, p. 65-72
|